News

Champions Biotechnology has reported a net loss of $623,234, or $0.02 per basic share, for the third quarter of fiscal 2009, compared to a net income of $311,006,

Primary endpoints were met in all of the clinical programs required for the submission of the new drug application (NDA), comprising a long-term safety study and four efficacy

Pursuant to the terms of the agreement, MDRNA will receive $7.25 million in upfront fees for the non-exclusive license. Additionally, the companies have entered into a separate agreement,

For the year ended December 31, 2008, the company reported a net loss of RMB52.3 million, or RMB0.39 per share, compared to a net income of RMB165.65 million,

According to the report, the Chinese health authorities investigated 33 products, including baby shampoo, made by Johnson & Johnson (J&J) after a US consumer group alleged that the

NeoStem, a developer of adult stem cell collection centers, has signed an agreement with Vincent Giampapa to open a new stem cell collection center at the Giampapa Institute

For the year ended December 31, 2008, the company reported a net loss of C$1.54 million, compared to a net loss of C$1.35 million for the year ended

The sale of the shares was achieved partly through market sales under Rule 144 of the US Securities Act of 1933, and, partly through a sale directly to

Gains on sales of securities and dividend income were 39.0% of invested capital for the year ended December 31, 2008, compared with up 57.6 for the year 2007.